Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$44.79 after a previous close of US$44.66. During the day the price has varied from a low of USD44.49 to a high of USD45.97. The latest price was USD45.34 (25 minute delay). Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Best for day trading
Our top pick for
Dividend investing
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before the split, the next day you would own 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
| Open | US$44.79 |
|---|---|
| High | US$45.97 |
| Low | US$44.49 |
| Close | US$45.34 |
| Previous close | US$44.66 |
| Change | US$0.68 |
| Change % | 1.5226% |
| Volume | 7,083,893 |
| 52-week range | US$39.0364 - US$62.2977 |
|---|---|
| 50-day moving average | US$41.6818 |
| 200-day moving average | US$48.3492 |
| Target price | US$50.68 |
| PE ratio | N/A |
| Dividend yield | US$2.34 (5.63%) |
| Earnings per share (TTM) | US$-3.1 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $45.34
| 1 week (2024-07-18) | 6.96% |
|---|---|
| 1 month (2024-06-25) | 7.47% |
| 3 months (2024-04-25) | 1.43% |
| 6 months (2024-01-25) | -8.61% |
| 1 year (2023-07-25) | -28.90% |
|---|---|
| 2 years (2022-07-25) | -37.75% |
| 3 years (2021-07-23) | -33.66% |
| 5 years (2019-07-25) | -0.13% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 31.3462. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$18.2 billion (£14.1 billion).
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$39.0364 up to US$62.2977. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.439. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
| Revenue TTM | US$45.5 billion |
|---|---|
| Operating margin TTM | 19.25% |
| Gross profit TTM | US$36.4 billion |
| Return on assets TTM | 5.39% |
| Return on equity TTM | -25.33% |
| Profit margin | -13.5% |
| Book value | 8.135 |
| Market capitalisation | US$86.4 billion |
TTM: trailing 12 months
Dividend payout ratio: 2.52% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 2.52% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.63% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 5.63% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.34 per share.
While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 31 July 2024. The latest dividend was paid out to all shareholders who bought their shares by 4 July 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.16 |
|---|---|
| Total ESG percentile | 52.58 |
| Environmental score | 3.83 |
| Environmental score percentile | 4 |
| Social score | 18.82 |
| Social score percentile | 4 |
| Governance score | 14.02 |
| Governance score percentile | 4 |
| Level of controversy | 2 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Consider these benefits and drawbacks before you invest in uranium stocks.
What to know before investing in this young but rapidly growing industry that protects against cybercrimes.
CommSec Pocket and Raiz Invest both micro-invest into the stock market, so what are the differences and why should you pick one over the other?
Learn what an initial public offering (IPO) is, how an IPO works and the advantages and risks of IPOs.
If you’re thinking of investing in gold, our guide will explain how and where to buy gold in Australia as well as the pros and cons of investing in it.
Here's a guide to your different investment options, the benefits of investing in silver and the possible risks.
Join the world’s largest social trading network and learn from experienced forex traders with eToro Australia.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.